Peptides for Hair Growth: GHK-Cu, TB-500, and What the Research Shows

Copper peptides lead the evidence for peptide-based hair regrowth. Here's what's proven, what's promising, and what's hype.

Research Digest6 min readApril 8, 2026

Why Peptides for Hair?

Hair loss affects roughly 50% of men and 25% of women by age 50. The standard treatments — minoxidil and finasteride — work but have limitations: minoxidil requires twice-daily application with modest regrowth, and finasteride carries sexual side effect concerns that deter many users. Peptides offer a different mechanistic approach. Rather than blocking DHT (finasteride) or dilating blood vessels (minoxidil), peptide-based strategies target the hair follicle growth cycle directly — extending the anagen (growth) phase, activating follicular stem cells, and supporting the dermal papilla cells that drive hair formation.

GHK-Cu: The Strongest Evidence

GHK-Cu (copper tripeptide) has the most evidence of any peptide for hair applications. It's a naturally occurring peptide that declines with age — from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 — and this decline correlates with both skin aging and thinning hair. GHK-Cu supports hair through multiple mechanisms: it stimulates dermal papilla cell proliferation, promotes blood vessel formation around follicles, upregulates collagen and extracellular matrix proteins, and modulates expression of over 4,000 genes involved in tissue remodeling. A 2025 clinical study demonstrated that copper peptides combined with minoxidil for androgenetic alopecia produced enhanced regrowth compared to standard treatments. GHK-Cu is available in both topical formulations (serums, scalp treatments) and injectable forms. For hair specifically, topical application to the scalp is the most common approach.

Thymosin Beta-4 / TB-500: Follicle Stem Cell Activation

Thymosin beta-4 (the parent compound of TB-500) has direct evidence for promoting hair growth in animal models. A study published in PLoS One demonstrated that thymosin beta-4 induced hair growth in mice, and a comprehensive review in the Journal of Cellular and Molecular Medicine detailed its mechanisms: activation of hair follicle stem cells, promotion of the anagen (growth) phase, and modulation of Wnt signaling — the key pathway governing follicle regeneration. TB-500 (the active fragment used therapeutically) is primarily discussed as an injectable for systemic recovery, but its hair growth potential is a secondary benefit that practitioners note. The evidence is preclinical — no human hair growth trials exist for TB-500 specifically.

Emerging: PTD-DBM and Wnt Pathway Peptides

A newer research direction targets the CXXC5-Dvl interaction, which suppresses Wnt/beta-catenin signaling in hair follicles. The peptide PTD-DBM disrupts this interaction, reactivating Wnt signaling and promoting hair follicle neogenesis. Research has shown this pathway is involved in DHT-induced androgenetic alopecia, and Wnt pathway activation represents a fundamentally different approach from existing treatments. However, PTD-DBM is still in early research stages — no clinical products are available, and human trial data is limited. The broader field of follicle neogenesis — growing entirely new hair follicles rather than just maintaining existing ones — is advancing rapidly, with peptide-based approaches among the most promising strategies.

How Peptides Compare to Standard Treatments

Minoxidil produces modest regrowth in about 40% of users and primarily works by increasing blood flow to follicles. Finasteride blocks DHT conversion and is more effective (up to 90% halting progression) but carries sexual side effect concerns. Peptides target different mechanisms — follicle stem cell activation, growth factor modulation, and extracellular matrix support. This makes them potentially complementary to standard treatments rather than replacements. The clinical study combining copper peptides with minoxidil showed this synergy in practice. For someone just starting to address hair loss: finasteride and minoxidil remain the evidence-backed first line. GHK-Cu topical application is a reasonable addition with minimal risk. TB-500 and newer peptides are more speculative.

Key Findings

GHK-Cu has the strongest peptide evidence for hair — it stimulates dermal papilla cells and modulates 4,000+ tissue remodeling genes
GHK-Cu levels decline ~60% from age 20 to 60, correlating with hair thinning
Thymosin beta-4 promoted hair growth in animal models via follicle stem cell activation and Wnt signaling
Copper peptides combined with minoxidil showed enhanced regrowth vs standard treatment alone in a clinical study
PTD-DBM targets the CXXC5-Dvl/Wnt pathway for follicle neogenesis — early but promising research

Limitations & Caveats

Most peptide hair growth evidence is preclinical — large-scale human RCTs are lacking
TB-500 has no published human hair growth trials; evidence extrapolates from thymosin beta-4 animal data
PTD-DBM and Wnt pathway peptides are still in early research with no commercial products
Peptides should be viewed as complementary to standard treatments (minoxidil, finasteride), not replacements
Individual response to topical peptides varies significantly